Beacon Investment Advisory Services Inc. lifted its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 271.1% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 63,660 shares of the biopharmaceutical company’s stock after buying an additional 46,504 shares during the quarter. Beacon Investment Advisory Services Inc.’s holdings in Gilead Sciences were worth $5,158,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. BlackRock Inc. boosted its position in Gilead Sciences by 1.9% during the second quarter. BlackRock Inc. now owns 104,906,494 shares of the biopharmaceutical company’s stock valued at $7,425,281,000 after purchasing an additional 1,937,031 shares in the last quarter. Vanguard Group Inc. boosted its position in Gilead Sciences by 2.4% during the second quarter. Vanguard Group Inc. now owns 92,841,960 shares of the biopharmaceutical company’s stock valued at $6,571,355,000 after purchasing an additional 2,148,697 shares in the last quarter. Bank of New York Mellon Corp boosted its position in Gilead Sciences by 1.0% during the second quarter. Bank of New York Mellon Corp now owns 30,881,405 shares of the biopharmaceutical company’s stock valued at $2,185,784,000 after purchasing an additional 310,607 shares in the last quarter. FMR LLC boosted its position in Gilead Sciences by 1.1% during the second quarter. FMR LLC now owns 23,037,303 shares of the biopharmaceutical company’s stock valued at $1,630,581,000 after purchasing an additional 258,005 shares in the last quarter. Finally, Northern Trust Corp boosted its position in Gilead Sciences by 0.7% during the second quarter. Northern Trust Corp now owns 16,430,476 shares of the biopharmaceutical company’s stock valued at $1,162,949,000 after purchasing an additional 116,780 shares in the last quarter. 75.84% of the stock is currently owned by institutional investors and hedge funds.

In other news, Chairman John C. Martin sold 50,000 shares of the firm’s stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $83.56, for a total value of $4,178,000.00. Following the completion of the transaction, the chairman now directly owns 3,046,766 shares in the company, valued at $254,587,766.96. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Gregg H. Alton sold 15,000 shares of the firm’s stock in a transaction dated Friday, December 1st. The stock was sold at an average price of $74.64, for a total value of $1,119,600.00. Following the completion of the transaction, the executive vice president now owns 70,988 shares of the company’s stock, valued at $5,298,544.32. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 578,333 shares of company stock valued at $44,100,508. Company insiders own 1.30% of the company’s stock.

A number of brokerages recently weighed in on GILD. Vetr downgraded Gilead Sciences from a “buy” rating to a “hold” rating and set a $91.25 price objective on the stock. in a research report on Monday, January 29th. Citigroup raised Gilead Sciences from a “neutral” rating to a “buy” rating and dropped their price objective for the company from $88.80 to $76.00 in a research report on Tuesday, January 30th. Bank of America raised their price objective on Gilead Sciences from $82.00 to $87.00 and gave the company a “neutral” rating in a research report on Wednesday. Morgan Stanley dropped their price objective on Gilead Sciences from $87.00 to $84.00 and set an “equal weight” rating on the stock in a research report on Wednesday. Finally, Barclays reaffirmed an “overweight” rating and set a $90.00 price objective on shares of Gilead Sciences in a research report on Wednesday, October 11th. One equities research analyst has rated the stock with a sell rating, twelve have given a hold rating, seventeen have assigned a buy rating and two have given a strong buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $85.58.

Gilead Sciences, Inc. (NASDAQ GILD) opened at $82.76 on Thursday. Gilead Sciences, Inc. has a 12 month low of $63.76 and a 12 month high of $89.54. The stock has a market capitalization of $108,080.00, a PE ratio of 9.42, a PEG ratio of -1.73 and a beta of 1.22. The company has a quick ratio of 3.56, a current ratio of 3.68 and a debt-to-equity ratio of 1.10.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Tuesday, February 6th. The biopharmaceutical company reported $1.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.67 by $0.11. Gilead Sciences had a return on equity of 57.15% and a net margin of 42.22%. The firm had revenue of $5.95 billion during the quarter, compared to analysts’ expectations of $5.71 billion. During the same period last year, the business posted $2.70 earnings per share. The company’s revenue for the quarter was down 18.7% compared to the same quarter last year. research analysts anticipate that Gilead Sciences, Inc. will post 8.53 EPS for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 29th. Stockholders of record on Friday, March 16th will be paid a $0.57 dividend. This represents a $2.28 annualized dividend and a dividend yield of 2.75%. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.52. The ex-dividend date is Thursday, March 15th. Gilead Sciences’s dividend payout ratio (DPR) is presently 23.66%.

COPYRIGHT VIOLATION WARNING: “Beacon Investment Advisory Services Inc. Purchases 46,504 Shares of Gilead Sciences, Inc. (GILD)” was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this report on another domain, it was stolen and republished in violation of US & international copyright and trademark laws. The correct version of this report can be accessed at https://www.thecerbatgem.com/2018/02/08/beacon-investment-advisory-services-inc-purchases-46504-shares-of-gilead-sciences-inc-gild.html.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.